Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

H1N1 Vaccine With Adjuvant Would Need Twice The Follow-up, FDA Recommends

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA's Vaccines and Related Biological Products Advisory Committee meets July 23 to discuss clinical trials for vaccines against the 2009 H1N1 flu virus.

You may also be interested in...



Two-Dose H1N1 Vaccination Might Be Optimal, But Would Stress Supply

An FDA panel said the H1N1 flu vaccine should be given in two doses when the probable vaccine campaign starts in the fall, but government officials at the meeting said there will not likely be enough vaccine available at that point to follow that advice

Two-Dose H1N1 Vaccination Might Be Optimal, But Would Stress Supply

An FDA panel said the H1N1 flu vaccine should be given in two doses when the probable vaccine campaign starts in the fall, but government officials at the meeting said there will not likely be enough vaccine available at that point to follow that advice

Adjuvanted H1N1 Vaccine Excites FDA Panel, But Jury Is Still Out

Pending further data on adjuvants from firms and NIH, FDA's Vaccines and Related Biological Products Advisory Committee is comfortable with FDA's plans to license unadjuvanted H1N1 flu vaccines under the strain change process.

Related Content

Topics

UsernamePublicRestriction

Register

PS069722

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel